Sino Biopharm profit soars, boosted by innovative drugs

Sino Biopharmaceutical (HKEX: 1177) reported a robust 50.1% increase in profit attributable to owners, reaching RMB 3.5 billion for the year ended December 31, 2024, alongside revenue which climbed 10.2% to RMB 28.87 billion. This surge was propelled by growth in revenue from innovative products and a pre-tax gain of RMB 1.71 billion from the disposal of CP Qingdao. The company's investment in Research and Development, totaling RMB 5.49 billion, demonstrates its commitment to innovation. Sino Biopharm launched six innovative products and had 28 generic drugs approved during the year. In line with its strong financial performance, the board has recommended a final dividend of HKD 0.04 per share, bringing the total dividend for the year to HKD 0.07 per share, payable July 10th, 2025, to shareholders of record on June 23, 2025.